ObjectiveTo investigate the effect of meropenem combined with norvancomycin in the treatment of severe pulmonary infection patients and the effects on respiratory index, serum macrophage inflammatory protein-1 alpha (MIP-1α), soluble myeloid cell trigger receptor-1 (sTREM-1) and prognosis. Methods82 cases of severe pulmonary infection admitted to our hospital from April 2016 to November 2016 were selected. They were randomly divided into observation group and control group, 41 cases in each group. The control group were treated with meropenem, and the observation group was treated with norvancomycin based on the treatment of the control group. The therapeutic effect, respiratory index and serum inflammatory factors of the two groups were compared. ResultsAfter 2 weeks of treatment, the total effective rate of treatment in the observation group (97.56%) was significantly higher than that of the control group (80.49%), and the clinical effect was better than that of the control group, the difference was statistically significant (P＜0.05). The PaCO2 of the observation group was significantly lower than that of the control group, and PaO2 was significantly higher than that of the control group (P＜0.01). The levels of MIP-lα, sTREM-1 and PCT in the observation group were significantly lower than those in the control group, and the levels of APN were significantly higher than those in the control group (P＜0.01). ConclusionMeropenem combined with norvancomycin is effective in the treatment of severe pulmonary infection, it is beneficial to improve the patient′s respiratory function and the state of inflammation, and promote the recovery of the patients. It is worth popularizing.

无